Triglyceride News and Research

RSS
Triglycerides are a type of fat in the bloodstream and fat tissue. Too much of this type of fat can contribute to the hardening and narrowing of your arteries. This puts you at risk of having a heart attack or stroke. Diseases such as diabetes, obesity, kidney failure or alcoholism can cause high triglycerides. Often, high triglycerides occur along with high levels of cholesterol, another type of fat. Triglycerides are measured along with cholesterol as part of a blood test. Normal triglyceride levels are below 150. Levels above 200 are high.
APhA to highlight increasing role of pharmacists in improving health, well-being

APhA to highlight increasing role of pharmacists in improving health, well-being

Risk of late onset TRAS in living unrelated donor kidney recipients

Risk of late onset TRAS in living unrelated donor kidney recipients

An overview on low-carbohydrate diets

An overview on low-carbohydrate diets

Chemicals in non-stick cookware elevates cholesterol level among children: Report

Chemicals in non-stick cookware elevates cholesterol level among children: Report

Genome-wide study identifies key genetic variant associated with nonalcoholic fatty liver disease

Genome-wide study identifies key genetic variant associated with nonalcoholic fatty liver disease

Research confirms genetic link to advanced fatty liver disease

Research confirms genetic link to advanced fatty liver disease

Amarin provides progress update on MARINE and ANCHOR trials for treating elevated triglyceride levels

Amarin provides progress update on MARINE and ANCHOR trials for treating elevated triglyceride levels

Amarin completes enrollment in AMR101 Phase 3 MARINE clinical trial

Amarin completes enrollment in AMR101 Phase 3 MARINE clinical trial

Lexicon Pharmaceuticals updates key progress in clinical pipeline

Lexicon Pharmaceuticals updates key progress in clinical pipeline

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

SORT1 pathway holds promise as new target for therapeutic intervention for LDL cholesterol reduction

SORT1 pathway holds promise as new target for therapeutic intervention for LDL cholesterol reduction

Research findings show normal rise and fall in triglycerides

Research findings show normal rise and fall in triglycerides

Intra-Cellular Therapies ITI-007 Phase Ib/II clinical trial for schizophrenia meets primary endpoint

Intra-Cellular Therapies ITI-007 Phase Ib/II clinical trial for schizophrenia meets primary endpoint

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

HTG patients face increased risk for heart disease, stroke: Study

HTG patients face increased risk for heart disease, stroke: Study

Scientists find major shortcomings in assessing CVD risk in HIV patients

Scientists find major shortcomings in assessing CVD risk in HIV patients

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Research findings could offer new approach to diabetes therapy, nutrition experts say

Research findings could offer new approach to diabetes therapy, nutrition experts say

New findings show why some people suffer from high levels of triglycerides

New findings show why some people suffer from high levels of triglycerides

Biospherics acquires worldwide patent rights to Dtagatose from UKRF

Biospherics acquires worldwide patent rights to Dtagatose from UKRF

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.